Insulin-like growth factor I receptor density on CD4+T-lymphocytes from active early steroid- and DMARD-naïve rheumatoid arthritis patients is up-regulated and not influenced by 1 year of clinically effective treatment.
The IGF-IR density on CD4+T-lymphocytes was studied using flow cytometry in 40 early steroid- and DMARD-naïve rheumatoid arthritis (RA) patients before and after 52 weeks of treatment with methotrexate+placebo or methotrexate+cyclosporine A and in 15 controls. RA patients had increased IGF-IR density on CD4+T-lymphocytes at week 0 and week 52, irrespective of treatment. IGF-IR-positive CD4+T-lymphocytes fraction decreased during treatment, but neither at week 0 nor at week 52 did it differ from healthy controls. No correlations were found to disease activity parameters.
Department of Rheumatology, Aarhus University Hospital, Norrebrogade 44, Building A1, 8000 Aarhus, Denmark. trine_bay@dadlnet.dk
Trine Bay
TB
Laurberg
Torkell
T
Ellingsen
Jonas
J
Thorsen
Bjarne Kuno
BK
Møller
Ib
I
Hansen
Ulrik
U
Tarp
Merete Lund
ML
Hetland
Kim
K
Hørslev-Petersen
Allan
A
Flyvbjerg
Jan
J
Frystyk
Kristian
K
Stengaard-Pedersen
D000328:Adult; D000368:Aged; D018501:Antirheumatic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism*; D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects / Q000378:metabolism*; D004357:Drug Synergism; D004359:Drug Therapy, Combination / Q000379:methods; D005260:Female; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D017526:Receptor, IGF Type 1 / Q000096:biosynthesis / Q000378:metabolism*; D013256:Steroids / Q000008:administration & dosage / Q000627:therapeutic use*; D015854:Up-Regulation / Q000187:drug effects* / Q000276:immunology; D055815:Young Adult
D018501:Antirheumatic Agents; D013256:Steroids; D007334:Insulin-Like Growth Factor I; D017526:Receptor, IGF Type 1
Clin Exp Rheumatol. 2005 Jul-Aug;23(4):505-12
16095120
J Immunol. 2007 Mar 1;178(5):3281-7
17312178
J Rheumatol. 2001 Jan;28(1):29-34
11196538
Cytokine Growth Factor Rev. 1999 Mar;10(1):5-14
10379908
J Rheumatol. 1996 Sep;23(9):1539-42
8877921
J Biol Chem. 1997 Jan 3;272(1):154-61
8995241
Arthritis Rheum. 2006 May;54(5):1401-9
16645967
Rheumatology (Oxford). 2005 Jan;44(1):120-5
15466894
Ann Rheum Dis. 2007 Feb;66(2):151-7
16905577
J Clin Invest. 1988 Sep;82(3):950-7
3262126
Int J Biochem Cell Biol. 2007;39(5):890-909
17113337
J Rheumatol. 1995 Jun;22(6):1060-4
7674231
Endocrinology. 1992 Nov;131(5):2244-50
1425423
Eur J Immunol. 1995 Apr;25(4):931-5
7737296
Clin Exp Immunol. 2005 Mar;139(3):526-33
15730399